Hypertension treatment in a medicare population: Adherence and systolic blood pressure control*

https://doi.org/10.1016/j.clinthera.2007.05.010Get rights and content

Abstract

Background:

Despite substantial trial evidence that demonstrates the effectiveness of pharmacologic treatment for reducing blood pressure (BP) and cardiovascular events, many patients are nonadherent to their hypertension treatment.

Objectives:

The purpose of this study was to examine patient adherence to hypertension medications using pharmacy data (ie, outpatient, inpatient, and mail-order prescriptions) and the association between adherence measures and systolic BP (SBP) control.

Methods:

The study included Medicare+Choice beneficiaries (aged ≥ 65 years) who were continuously enrolled in an integrated delivery system in 2003, and who had documented hypertension and received ≥1 hypertension drug in 2002. This analysis used automated clinical data and the 2000 US Census. We estimated 2 measures of hypertension treatment adherence in 2003 using the supply of dispensed drugs in days (proportion of days covered ≥80%): (1) adherence to ≥1 hypertension drug; and (2) adherence to the full hypertension treatment regimen. We defined the regimen by the number of hypertension drugs used concurrently in 2002. We assessed adherence annually and during the 30, 60, and 90 days before an SBP measurement. Logistic regression was used to examine the association between adherence and the number of drugs in the hypertension regimen, as well as the association between adherence and elevated SBP (≥140 mm Hg). We adjusted for patient sociodemographic and clinical characteristics.

Results:

The majority (52.8%) of patients had multidrug hypertension regimens. In 2003, 87.3% of subjects were adherent to ≥ 1 hypertension drug; 72.1% were adherent to their full regimen. After adjustment, we found that subjects with multidrug regimens were significantly more likely to be adherent to ≥ 1 drug and significantly less likely to be adherent to their full regimen, compared with patients on a 1-drug regimen. Over one-third of subjects had elevated SBP in 2003. Both adherence measures were associated with lower odds of having elevated SBP (eg, odds ratio = 0.87 [95% CI, 0.84–0.89] for adherence to the full regimen). For subjects with multidrug regimens, partial adherence and nonadherence to the regimen were associated with higher odds of having elevated SBP.

Conclusions:

Adherence measures using automated pharmacy data can identify patients who are nonadherent to their drug treatment regimen and who are more likely to have inadequately controlled BP. Adherence measures that account for the number of drugs in a patients' drug regimen might help identify additional patients at risk for poor BP outcomes due to partial treatment adherence.

References (39)

  • ChobanianA.V. et al.

    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report

    JAMA

    (2003)
  • HajjarI. et al.

    Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000

    JAMA

    (2003)

  • Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)

    JAMA

    (1991)
  • NealB. et al.

    Effects ofACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials

    Lancet

    (2000)
  • MoserM. et al.

    Clinical practice. Resistant or difficult-to-control hypertension

    N Engl J Med

    (2006)
  • GargJ.P. et al.

    Resistant hypertension revisited: A comparison of two university-based cohorts

    Am J Hypertens

    (2005)
  • MonaneM. et al.

    The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly

    Am J Hypertens

    (1997)
  • SchroederK. et al.

    How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials

    Arch Intern Med

    (2004)
  • BramleyT.J. et al.

    Relationship of blood pressure control to adherence with anti hypertensive monotherapy in 13 managed care organizations

    J Manag Care Pharm

    (2006)

  • The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

    JAMA

    (2002)
  • SteinerJ.F. et al.

    Appropriate reductions in compliance among well-controlled hyper tensive patients

    J Clin Epidemiol

    (1991)
  • ChooP.W. et al.

    Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to anti hypertensive therapy

    Med Care

    (1999)
  • GrantR.W. et al.

    Medication adherence before an increase in anti hypertensive therapy: A cohort study using pharmacy claims data

    Clin Ther

    (2005)
  • Van WijkB.L. et al.

    Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation

    J Clin Epidemiol

    (2006)
  • ChapmanR.H. et al.

    Predictors of adherence with anti hypertensive and lipid-lowering therapy

    Arch Intern Med

    (2005)
  • PladevallM. et al.

    Clinical outcomes and adherence to medications measured by claims data in patients with diabetes

    Diabetes Care

    (2004)
  • IskedjianM. et al.

    Relationship between daily dose frequency and adherence to anti hypertensive pharmacotherapy: Evidence from a meta-analysis

    Clin Ther

    (2002)
  • Van WijkB.L. et al.

    The association between compliance with antihyper tensive drugs and modification of anti hypertensive drug regimen

    J Hypertens

    (2004)

    • Cited by (0)

    *

    The results from this study were presented in abstract form at the 11th Annual HMO Research Network Conference, April 4–6, 2005, Santa Fe, New Mexico, and at the Academy Health 2005 Annual Research Meeting, June 26–28, 2005, Boston, Massachusetts.

    View full text
    Copyright © 2007 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.